A survey A recent survey conducted by The Harris Poll in September 2024 highlights healthcare professionals' concerns about the treatment of schizophrenia and bipolar I disorder (BID). The study, commissioned by Alkermes, Inc., focused on the perspectives of more than 250 healthcare professionals in the U.S. who treat at least 10 patients with BID and 2 with schizophrenia per month.
Key concerns about medication and quality of life
One of the main challenges for the physicians surveyed is medication adherence. 981% of respondents believe that patients' quality of life is as important as symptom control. This aspect reflects the challenges of finding effective and long-term sustainable treatments.
661 people with TBI report a good quality of life, while only 211 people with schizophrenia share this perception. Furthermore, patients with bipolar disorder change medications an average of seven times throughout their lives, while patients with schizophrenia change medications eight times. The main reasons for switching are medication ineffectiveness and intolerable side effects.
Impact of medication changes and treatment approaches
Physicians emphasize that frequent medication changes negatively affect patients' quality of life. 771% of respondents stated that these changes make long-term symptom control difficult. Furthermore, when choosing treatments, 68% of physicians consider it crucial that new advances be included in clinical guidelines, and 65% of physicians value the accessibility of treatments through insurance.
Treatment success depends on patients' ability to adhere to their medication and the frequency with which they experience symptoms. Doctors prioritize treatments that minimize side effects and improve quality of life.
In conclusion, this survey highlights the challenges in the treatment of schizophrenia and bipolar disorder. It underscores the need for more consistent and accessible approaches to managing these mental illnesses.
